- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04708782
특발성 폐섬유증 환자에서 흡입형 트레프로스티닐의 효능 및 안전성 연구 (TETON-1)
특발성 폐 섬유증 환자에서 흡입된 트레프로스티닐의 효능 및 안전성에 대한 무작위, 이중 맹검, 위약 대조 3상 연구
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
연구 개요
상태
상세 설명
Study RIN-PF-301 is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic will be required at Weeks 4, 8, 16, 28, 40, and 52.
Efficacy assessments include spirometry (FVC), time to clinical worsening, time to first acute exacerbation of IPF, overall survival, King's Brief Interstitial Lung Disease (K-BILD) questionnaire, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, supplemental oxygen use, and lung diffusion capacity (DLCO). Safety assessments include the development of adverse events (AEs)/serious adverse events (SAEs), vital signs, clinical laboratory parameters, and electrocardiogram (ECG) parameters.
Subjects who complete the Week 52 Visit may be offered the opportunity to enter an open-label extension (OLE) study after completing the final study visit.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- The University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, 미국, 85012
- Arizona Pulmonary Specialists, Ltd.
-
Phoenix, Arizona, 미국, 85006
- Banner University Medical Center-Phoenix
-
Phoenix, Arizona, 미국, 85013
- St. Joseph's Hospital and Medical Center - Norton Thoracic Institute
-
Tucson, Arizona, 미국, 85724
- University of Arizona
-
-
California
-
La Jolla, California, 미국, 92037
- UC San Diego Health
-
Los Angeles, California, 미국, 90095
- David Geffen School of Medicine at UCLA
-
Newport Beach, California, 미국, 92663
- NewportNativeMD, Inc
-
Orange, California, 미국, 92868
- University of California, Irvine
-
Palm Springs, California, 미국, 92262
- Palmtree Clinical Research, Inc.
-
Sacramento, California, 미국, 95817
- UC Davis Health Medical Center
-
San Francisco, California, 미국, 94143
- University of California - San Francisco
-
Stanford, California, 미국, 94305
- Stanford University Medical Center
-
-
Colorado
-
Denver, Colorado, 미국, 80206
- National Jewish Health
-
-
Florida
-
Clearwater, Florida, 미국, 33765
- St. Francis Sleep Allergy & Lung Institute
-
Gainesville, Florida, 미국, 32610
- University of Florida Health at Shands
-
Jacksonville, Florida, 미국, 32224
- Mayo Clinic Florida
-
Jacksonville, Florida, 미국, 32204
- Ascension St. Vincent's
-
Jacksonville, Florida, 미국, 32209
- University of Florida
-
Kissimmee, Florida, 미국, 34741
- Pulmonary Disease Specialists, PA d/b/a PDS Research
-
Orlando, Florida, 미국, 32803
- Central Florida Pulmonary Group, PA
-
St. Petersburg, Florida, 미국, 33704
- Coastal Pulmonary & Critical Care PLC
-
Tampa, Florida, 미국, 33606
- University of South Florida Health
-
Weston, Florida, 미국, 33331
- Cleveland Clinic Florida
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory University Hospital
-
Atlanta, Georgia, 미국, 30309
- Piedmont Healthcare Atlanta
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96813
- The Queen's Medical Center
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Northwestern Memorial Hospital
-
Chicago, Illinois, 미국, 60612
- Rush University Medical Center Outpatient Pulmonary Clinic
-
Maywood, Illinois, 미국, 60153
- Loyola University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46250
- Community Health Network
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- The University of Kansas Medical Center
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40202
- University of Louisville
-
Louisville, Kentucky, 미국, 40202
- Norton Pulmonary Specialists
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70112
- Tulane University Medical Center
-
New Orleans, Louisiana, 미국, 70112
- LSU Health Sciences Center New Orleans
-
Shreveport, Louisiana, 미국, 71103
- LSU Health Science Center Shreveport
-
-
Maryland
-
Baltimore, Maryland, 미국, 21224
- Johns Hopkins Asthma & Allergy Center
-
Silver Spring, Maryland, 미국, 20904
- Adventist Healthcare White Oak Medical CEnter
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, 미국, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan Int Med Pulmonary and critical care
-
Detroit, Michigan, 미국, 48202
- Henry Ford Hospital
-
Royal Oak, Michigan, 미국, 48073
- Corewell Health William Beaumont Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- University of Minnesota
-
Rochester, Minnesota, 미국, 55902
- Mayo Clinic
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Chesterfield, Missouri, 미국, 63017
- The Lung Research Center
-
Kansas City, Missouri, 미국, 64111
- Saint Luke's Hospital of Kansas City
-
St Louis, Missouri, 미국, 63110
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68124
- Creighton University Clinical Research Office
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- University of New Mexico Health Sciences Center
-
-
New York
-
Commack, New York, 미국, 11725
- Stony Brook Advanced Specialty Care
-
Liverpool, New York, 미국, 13088
- St Joseph's Physician's Pulmonary Health
-
New Hyde Park, New York, 미국, 11040
- Northwell Health
-
Rochester, New York, 미국, 14642
- University of Rochester Medical center
-
The Bronx, New York, 미국, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Greensboro, North Carolina, 미국, 27403
- PulmonIx, LLC
-
Greenville, North Carolina, 미국, 27834
- East Carolina University and Leo Jenkins Cancer Center
-
Winston-Salem, North Carolina, 미국, 27103
- Southeastern Research Center
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45267
- University of Cincinnati
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic
-
Columbus, Ohio, 미국, 43221
- The Ohio State University Wexner Medical Center - Martha Morehouse Medical Pavilion
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, 미국, 97220
- The Oregon Clinic, PC
-
-
Pennsylvania
-
Hershey, Pennsylvania, 미국, 17033
- Penn State Milton S. Hershey Medical Center/Penn State College of Medicine
-
Philadelphia, Pennsylvania, 미국, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19140
- Temple Lung Center
-
Philadelphia, Pennsylvania, 미국, 19107
- Thoams Jefferson,Hospital University
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, 미국, 29203
- Prisma Health Midlands
-
Rock Hill, South Carolina, 미국, 29732
- Clinical Research of Rock Hill
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37919
- Statecare Pulmonary Consultants
-
Nashville, Tennessee, 미국, 37204
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, 미국, 75246
- Baylor University Medical Center
-
Dallas, Texas, 미국, 75390-8550
- Univrsity of Texas Southwestern Medical Center
-
Denison, Texas, 미국, 75020
- Premier Pulmonary Critical Care and Sleep Medicine
-
Houston, Texas, 미국, 77030
- The University of Texas Health Science Center at Houston
-
Houston, Texas, 미국, 77030
- Baylor Clinic-Baylor College of Medicine
-
McAllen, Texas, 미국, 78503
- A & A Research Consultants, LLC
-
McKinney, Texas, 미국, 75069
- Metroplex Pulmonary and Sleep Center PA
-
The Woodlands, Texas, 미국, 77380
- Renovatio Clinical Consultants, LLC
-
-
Utah
-
Murray, Utah, 미국, 84107
- Intermountain Medical Center
-
Salt Lake City, Utah, 미국, 84108
- University of Utah Health
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22903
- University of Virginia Health System
-
Falls Church, Virginia, 미국, 22042
- Inova Fairfax Hospital
-
Richmond, Virginia, 미국, 23230
- Pulmonary Associates of Richmond, Inc.
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
- University of Wisconsin School of Medicine and Public health
-
Milwaukee, Wisconsin, 미국, 53226
- Medical College of Wisconsin
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6Z1Y6
- St.Paul's Hospital
-
-
Ontario
-
Ajax, Ontario, 캐나다, L1S 2J5
- Dynamic Drug Advancement Limited
-
Hamilton, Ontario, 캐나다, L8N 4A6
- St. Joseph's Healthcare Hamilton
-
Toronto, Ontario, 캐나다, M5G 2C4
- Toronto General Hospital
-
-
Quebec
-
Québec, Quebec, 캐나다, G1V 4G5
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Universite
-
Trois-Rivières, Quebec, 캐나다, G8T 7A1
- Centre d'investigation Clinique Mauricie
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Subject gives voluntary informed consent to participate in the study.
- Subject is ≥40 years of age, inclusive, at the time of signing informed consent.
- The subject has a diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT Clinical Practice Guideline (Raghu 2018) and confirmed by central review of high-resolution computed tomography (HRCT) (performed within the previous 12 months), and if available, surgical lung biopsy.
- FVC ≥45% predicted at Screening.
- Subjects on pirfenidone or nintedanib must be on a stable and optimized dose for ≥30 days prior to Baseline. Concomitant use of both pirfenidone and nintedanib is not permitted.
- Women of childbearing potential must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will abstain from intercourse (when it is in line with their preferred and usual lifestyle) or use 2 medically acceptable, highly effective forms of contraception for the duration of the study, and at least 30 days after discontinuing study drug.
- Males with a partner of childbearing potential must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.
- In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.
Exclusion Criteria:
- Subject is pregnant or lactating.
- Subject has primary obstructive airway physiology: FEV1/FVC <0.70 at Screening.
- The subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.
- The subject has received any PAH-approved therapy, including prostacyclin therapy (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonists (selexipag), endothelin receptor antagonists, phosphodiesterase type 5 inhibitors (PDE5-Is), or soluble guanylate cyclase stimulators within 60 days prior to Baseline. As needed use of a PDE5-I for erectile dysfunction is permitted, provided no doses are taken within 48 hours of any study-related efficacy assessments.
- Use of any of the following medications: azathioprine (AZA), cyclosporine, mycophenolate mofetil, tacrolimus, oral corticosteroids (OCS) >20 mg/day or the combination of OCS+AZA+N-acetylcysteine within 30 days prior to Baseline; cyclophosphamide within 60 days prior to Baseline; or rituximab within 6 months prior to Baseline.
- The subject is receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
- Exacerbation of IPF or active pulmonary or upper respiratory infection within 30 days prior to Baseline. Subjects must have completed any antibiotic or steroid regimens for treatment of the infection or acute exacerbation more than 30 days prior to Baseline to be eligible. If hospitalized for an acute exacerbation of IPF or a pulmonary or upper respiratory infection, subjects must have been discharged more than 90 days prior to Baseline to be eligible.
- Uncontrolled cardiac disease, defined as myocardial infarction within 6 months prior to Baseline or unstable angina within 30 days prior to Baseline.
- In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or would impair study participation or cooperation.
- Use of any other investigational drug/device or participation in any investigational study in which the subject received a medical intervention (ie, procedure, device, medication/supplement) within 30 days prior to Screening. Subjects participating in non-interventional, observational, or registry studies are eligible.
- Life expectancy <6 months due to IPF or a concomitant illness.
- Acute pulmonary embolism within 90 days prior to Baseline.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Matching placebo inhaled using an ultrasonic nebulizer QID |
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Placebo administered QID |
|
실험적: Inhaled Treprostinil
Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose. |
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled treprostinil (6 mcg/breath) administered QID
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Absolute FVC From Baseline to Week 52
기간: Baseline to Week 52
|
The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. |
Baseline to Week 52
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to Clinical Worsening
기간: Baseline to Week 52
|
Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC. The number of participants with clinical worsening was reported. The time to first clinical worsening event was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. |
Baseline to Week 52
|
|
Time to First Acute Exacerbation of IPF
기간: Baseline to Week 52
|
An acute exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality. The number of participants with an exacerbation of IPF was reported. The time to first acute exacerbation of IPF was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. |
Baseline to Week 52
|
|
Overall Survival at Week 52
기간: Week 52
|
Vital status was assessed for all subjects at Week 52, including those who discontinued the study prematurely. The number of deaths by Week 52 was reported. The time to death was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. Note: Participants who discontinued from the study early had their time to death censored at Day 373 or last contact date when known to be alive (whichever occurred first), and participants with lung transplantation had their time to death censored at lung transplant date. Therefore, the number of deaths for this outcome measure differ from the overall number on deaths (reported in the Adverse Events section). |
Week 52
|
|
Change in % Predicted FVC From Baseline to Week 52
기간: Baseline to Week 52
|
The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight. |
Baseline to Week 52
|
|
Change in K-BILD Questionnaire Score From Baseline to Week 52
기간: Baseline to Week 52
|
The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms). Each of the 15 questions is scored from 1 (worst score) to 7 (best score). The scores for the 15 questions are added together and converted into a Total Score from 0 to 100. Higher scores indicate a better quality of life. |
Baseline to Week 52
|
|
Change in DLCO From Baseline to Week 52
기간: Baseline to Week 52
|
The DLCO measurement measures how well oxygen moves from the lungs to the blood. |
Baseline to Week 52
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Hwang S, Fuentes M, Lederer J, Mitkus S, Rivas-Fuentes S, Nathan SD. A plain language review of the TETON-1 and TETON-2 studies: inhaled treprostinil (Tyvaso) in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2026 Nov 2:1-10. doi: 10.1080/17476348.2026.2743298. Online ahead of print.
- Nathan SD, Smith P, Deng C, Golden J, Reynaud-Gaubert M, Farr G, Bregman B, Crossno PF, Harari S, Gupta N, Jouneau S, Adir Y, Molina-Molina M, Breytenbach N, Peterson L, Bell H, Zywot E, Rao Y, Flaherty KR, Cottin V, Behr J; TETON-1 and TETON-2 Trial Investigators. Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2026 Sep 23:aamag507. doi: 10.1093/ajrccm/aamag507. Online ahead of print.
- Nathan SD, Smith P, Deng C, King CS, De Salvo M, Weigt SS, Pandya S, Bandyopadhyay D, Lasky JA, Krishna R, Hambly N, Ramaswamy M, Kebbe J, Ettinger N, Gao J, Rao Y, Breytenbach N, Peterson L, Bell H, Behr J, Cottin V, Flaherty KR; TETON-1 Trial Investigators. Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2026 Jul 9;395(2):115-126. doi: 10.1056/NEJMoa2501488. Epub 2026 May 18.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .